Recombinant Mouse Leucine-rich repeat neuronal protein 4 (Lrrn4)

What is the molecular structure of mouse LRRN4 protein?

Mouse LRRN4 is a type I transmembrane protein consisting of 640 amino acids. Its structure includes an extracellular domain with 10 leucine-rich repeats (LRRs) and a fibronectin type III-like domain, a 21-amino acid transmembrane segment, and a 40-amino acid cytoplasmic domain. The protein's molecular weight typically appears between 110-130 kDa under reducing conditions in SDS-PAGE analysis, although the theoretical molecular weight is approximately 72 kDa . This discrepancy is likely due to post-translational modifications. The full-length recombinant mouse LRRN4 protein spans amino acids 20-733, with the mature protein beginning at Gln22 in most commercial preparations .

What is the expression pattern of LRRN4 in normal mouse tissues?

LRRN4 demonstrates a tissue-specific expression pattern. It is primarily expressed in:

• Central nervous system: particularly in the hippocampus and cortex

• Peripheral nervous system: found in approximately 8% of dorsal root ganglion (DRG) neurons, specifically small-sized neurons functioning as nociceptors

• Cardiovascular system: expressed in cardiomyocytes and ventricular tissues

• Other tissues: detected in lung and ovary

Expression studies using LRRN4-deficient mice with β-galactosidase reporter gene insertion have helped map tissue distribution patterns. LRRN4 expression in DRG neurons decreases following sciatic axotomy, suggesting its role in maintaining nociceptive circuits .

What are the recommended protocols for detecting mouse LRRN4 expression in tissue samples?

Detection of LRRN4 expression in tissues requires a multi-method approach:

Western Blot Analysis:

• Lyse tissues with buffer containing 150 mM NaCl, 50 mM Tris-HCl (pH 7.4), 1% Nonidet P-40, and proteinase inhibitor cocktail

• Perform electrophoresis using 10% sodium dodecyl sulfate-polyacrylamide gel

• Transfer to nitrocellulose membrane

• Use anti-LRRN4 antibody (1:1000, such as HPA009431 from Sigma-Aldrich)

• Include actin (1:10000) as internal control

• Expected band size: 106-123 kDa

Real-time PCR:

• Extract total RNA from tissues using TRIzol reagent

• Synthesize cDNA using reverse transcriptase

• Design primers specific to mouse LRRN4

• Normalize expression to housekeeping genes (GAPDH, β-actin)

Immunohistochemistry:

• Fix tissues in 4% paraformaldehyde

• Section tissues and perform antigen retrieval

• Block with normal serum

• Incubate with anti-LRRN4 primary antibody

• Use appropriate secondary antibody and visualization system

• Counterstain with hematoxylin

These methods have been validated in studies examining LRRN4 expression in heart, brain, and cancer tissues .

How should researchers design LRRN4 knockdown experiments in mouse models?

When designing LRRN4 knockdown experiments, researchers should consider:

shRNA Approach:

• Design multiple shRNA sequences targeting different regions of LRRN4 mRNA

  • Example: LRRN4-homo-842 has proven effective in previous studies

• Construct into lentivirus vectors with appropriate promoters

• Determine suitable multiplicity of infection (MOI) through titration experiments

• Transfect target cells and perform antibiotic selection

• Confirm knockdown efficiency by qPCR and western blot (target >50% reduction)

• Conduct subsequent characterization experiments only after confirming reduced expression

CRISPR-Cas9 Approach:

• Design guide RNAs targeting exonic regions of LRRN4

• Verify off-target effects using bioinformatics tools

• Establish stable knockdown cell lines

• Validate genomic modifications and expression reduction

Knockout Mouse Generation:

• Replace LRRN4 exons with reporter genes (e.g., β-galactosidase) through homologous recombination

• Verify gene deletion through PCR and protein expression through western blot

• Assess phenotypes in homozygous knockout mice, particularly focusing on hippocampus-dependent learning tasks

Each approach should include appropriate controls, including scrambled shRNA, empty vector controls, or wild-type littermates for knockout studies .

How does LRRN4 expression change in cardiac pathologies and what methodologies best capture these alterations?

LRRN4 demonstrates distinct expression patterns in different cardiac pathologies:

Expression Patterns:

• Normal hearts: High expression in donor hearts

• Dilated Cardiomyopathy (DCM): Significantly reduced expression

• Ischemic Heart Disease (IHD): Comparable expression to normal hearts

• Pressure overload-induced hypertrophic hearts: Significantly decreased expression

Methodology for Analysis:

• Tissue Collection Protocol:

  • Human heart samples from patients with DCM, IHD, and healthy donors

  • Mouse models: Pressure overload via transverse aortic constriction (TAC)

• Expression Analysis:

  • Western blot: Quantify protein levels with densitometry

  • Real-time PCR: Measure mRNA expression levels

  • Immunohistochemistry: Assess cellular localization and expression patterns

• Functional Correlation:

  • Echocardiography to assess cardiac function parameters

  • Histological analysis for fibrosis and cardiomyocyte hypertrophy

  • Correlation of LRRN4 levels with clinical parameters

• Mechanistic Investigation:

  • Investigate LRRN4 as a potential therapeutic target for DCM

  • Study its role as a cellular adhesion molecule in cardiac remodeling

The differential expression pattern suggests LRRN4 might be a specific biomarker for DCM but not IHD, and potentially a therapeutic target specifically for DCM with cardiac remodeling .

What experimental models best demonstrate the role of LRRN4 in colorectal cancer progression?

Research on LRRN4 in colorectal cancer (CRC) employs several complementary models:

In Silico Models:

• TCGA Database Analysis:

  • Compare LRRN4 expression between COAD (colon adenocarcinoma) and normal tissues

  • Correlate expression with clinical parameters and survival outcomes

  • Use UALCAN (http://ualcan.path.uab.edu) and GEPIA (http://gepia.cancer-pku.cn/) databases

  • Apply multivariate Cox regression to determine if LRRN4 is an independent prognostic factor

In Vitro Models:

• Cell Line Studies:

  • Use CRC cell lines with LRRN4 knockdown or overexpression

  • Assays: colony formation, flow cytometry, wound healing

  • Measure effects on cell proliferation, cell cycle, apoptosis, and migration

  • Western blot to assess pathway activation (Akt, p-Akt, ERK1/2, p-ERK1/2)

In Vivo Models:

• Mouse Xenograft Models:

  • Inject CRC cells with LRRN4 knockdown or overexpression subcutaneously

  • Monitor tumor growth, weight, and volume

  • Perform immunohistochemistry on tumor tissues

  • Analyze tumor-associated signaling pathways

Patient Cohort Studies:

• Tissue Microarray Analysis:

  • Collect primary CRC tissues and corresponding distant normal mucosa

  • Correlate LRRN4 expression with clinicopathological features

  • Perform Kaplan-Meier survival analysis

These models collectively demonstrate that high LRRN4 expression correlates with poor prognosis in CRC patients, and LRRN4 promotes cell proliferation and migration while inhibiting apoptosis in CRC cells .

What signaling pathways does LRRN4 interact with in cancer progression and how can these be experimentally validated?

LRRN4 interacts with several critical signaling pathways in cancer:

Identified Pathways:

• Ras/MAPK Pathway:

  • LRRN4 knockdown results in downregulation of ERK1/2 and p-ERK1/2

  • LRRN4 overexpression leads to upregulation of these proteins

• PI3K/Akt Pathway:

  • LRRN4 knockdown decreases Akt and p-Akt levels

  • Affects Akt phosphorylation at Ser473 and Thr308 sites

• TGF-β Signaling Pathway:

  • Significantly activated in high LRRN4 expression groups

  • Involved in epithelial-mesenchymal transition

• WNT Signaling Pathway:

  • Activated in correlation with high LRRN4 expression

  • Critical for colorectal cancer development

Experimental Validation Methods:

• Gene Set Enrichment Analysis (GSEA):

  • Identify enriched KEGG pathways in high vs. low LRRN4 expression samples

  • Use the Database for Annotation, Visualization and Integrated Discovery (DAVID)

  • Analyze Gene Ontology (GO) terms including cellular component, biological process, and molecular function

• Western Blot Analysis:

  • Assess pathway activation markers after LRRN4 knockdown/overexpression

  • Key proteins: Akt, p-Akt(Ser473), p-Akt(Thr308), ERK1/2, p-ERK1/2

  • Include both total and phosphorylated forms of proteins

• Pathway Inhibitor Studies:

  • Treat cells with specific pathway inhibitors (PI3K, MEK, TGF-β inhibitors)

  • Determine if inhibition rescues phenotypic effects of LRRN4 overexpression

• Co-Immunoprecipitation:

  • Identify direct protein-protein interactions with pathway components

  • Verify interactions using reciprocal co-IP experiments

• Luciferase Reporter Assays:

  • Measure pathway activation using specific reporters

  • Compare activity with LRRN4 manipulation

The interplay between LRRN4 and these pathways reveals its role in promoting malignant behaviors in cancer cells, potentially serving as a therapeutic target .

How does LRRN4 contribute to hippocampus-dependent memory formation and what are the molecular mechanisms underlying this function?

LRRN4's role in hippocampus-dependent memory involves specific temporal and spatial processes:

Memory Formation Characteristics:

• LRRN4-deficient (LRRN4^-/-^) mice demonstrate normal learning and short-term memory (up to 1 day)

• Memory retention defects appear at 4 days post-learning in hippocampus-dependent tasks

• Hippocampus-independent memory remains intact for at least 7 days

• This indicates LRRN4's specific role in long-lasting memory maintenance in the hippocampus

Experimental Approaches to Study Mechanisms:

• Behavioral Testing Protocol:

  • Morris water maze: Test spatial memory acquisition and retention

  • Contextual fear conditioning: Assess associative memory

  • Cued fear conditioning: Control for hippocampus-independent memory

  • Test memory at multiple time points (1 day, 4 days, 7 days post-learning)

• Electrophysiological Studies:

  • Long-term potentiation (LTP) recording in hippocampal slices

  • Field potential recordings at Schaffer collateral-CA1 synapses

  • Whole-cell patch-clamp recordings to assess synaptic transmission

• Molecular Analysis:

  • Examine protein synthesis pathways (mTOR, CREB activation)

  • Assess structural changes in dendritic spines using Golgi staining

  • Analyze immediate early gene expression (c-Fos, Arc) after learning

• Cell Adhesion Function:

  • LRRN4 may function as a synaptic adhesion molecule

  • Investigate protein-protein interactions with other cell adhesion molecules

  • Assess effects on synapse formation and maintenance

• Reporter Gene Studies:

  • Use β-galactosidase expression from LRRN4 locus in knockout mice

  • Map temporal and spatial activation patterns during memory formation

The specific deficit in long-term but not short-term hippocampal memory suggests LRRN4 may be involved in the consolidation phase of memory or in maintaining structural changes required for long-term memory storage .

What are the optimal storage and handling conditions for recombinant mouse LRRN4 protein to maintain its biological activity?

Maintaining recombinant mouse LRRN4 protein activity requires careful attention to storage and handling:

Storage Recommendations:

Reconstitution Protocol:

• Recombinant mouse LRRN4 is typically supplied as a lyophilized protein from a 0.2 μm filtered solution in PBS

• Reconstitute at the recommended concentration:

  • For carrier-free preparations: 500 μg/mL in PBS (human LRRN4) or 1 mg/mL in PBS (mouse LRRN4)

• Allow complete reconstitution by gently rotating the vial

• Do not vortex as this may damage protein structure

• After reconstitution, aliquot to minimize freeze-thaw cycles

Handling Precautions:

• Use a manual defrost freezer for storage

• Avoid repeated freeze-thaw cycles as they significantly reduce activity

• For cell culture applications, filter through a 0.22 μm filter before use

• Note that some protein loss may occur during filtration

• When working with the protein, keep on ice and use within the same day once thawed

Activity Testing:

• Functional activity can be measured by its ability to inhibit neurite outgrowth of E16-E18 rat embryonic cortical neurons when immobilized at 2.5 μg/mL on a 96-well plate

• Verify protein integrity by SDS-PAGE before experiments, looking for bands at 110-130 kDa under reducing conditions

Following these guidelines ensures maximum retention of biological activity for experimental applications .

What are the common challenges in generating functional LRRN4 knockout models and how can these be addressed?

Creating functional LRRN4 knockout models presents several challenges:

Challenge 1: Embryonic Lethality

• Issue: Complete knockout may affect development

• Solutions:

  • Generate conditional knockouts using Cre-loxP system

  • Use tissue-specific promoters (neuron-specific, cardiomyocyte-specific)

  • Employ inducible knockout systems (tamoxifen-inducible)

Challenge 2: Compensatory Mechanisms

• Issue: Other LRRN family members (LRRN1-3) may compensate for LRRN4 loss

• Solutions:

  • Generate double or triple knockouts for multiple LRRN family members

  • Use acute knockdown approaches (shRNA, CRISPR) to minimize compensation

  • Analyze expression changes in other family members following LRRN4 deletion

Challenge 3: Phenotype Detection

• Issue: Subtle phenotypes may be missed in standard assays

• Solutions:

  • Use sensitive behavioral paradigms for memory testing

  • Conduct testing at multiple time points (1, 4, 7 days) post-learning

  • Combine with electrophysiological recordings from hippocampal slices

  • Employ challenging learning tasks that require hippocampal function

Challenge 4: Validation of Knockout

• Issue: Ensuring complete protein elimination

• Solutions:

  • Verify gene deletion by PCR of genomic DNA

  • Confirm absence of protein by western blot with antibodies against multiple epitopes

  • Use β-galactosidase staining if replacing with reporter gene

  • Perform RT-PCR to detect any residual transcript

Challenge 5: Background Strain Effects

• Issue: Different mouse strains may show variable phenotypes

• Solutions:

  • Backcross to a consistent genetic background (C57BL/6 recommended)

  • Include littermate controls

  • Consider testing the knockout on multiple genetic backgrounds

Successful LRRN4 knockout models have been generated by replacing exons with the β-galactosidase gene through homologous recombination. These models have proven valuable for studying the role of LRRN4 in hippocampus-dependent memory retention and could be adapted to study its function in cardiac and cancer models .

What are the most promising applications of recombinant mouse LRRN4 in studying neurological disorders beyond memory function?

Recombinant mouse LRRN4 offers several promising research avenues for neurological disorders:

Neuropathic Pain Research:

• LRRN4 is expressed in approximately 8% of DRG neurons that function as nociceptors

• Its expression decreases following sciatic axotomy, suggesting involvement in nociceptive circuits

• Research applications:

  • Use recombinant LRRN4 as a tool to identify specific nociceptor populations

  • Study its interactions with pain-related receptors and channels

  • Investigate whether LRRN4 modulation affects pain thresholds in animal models

  • Explore potential as a therapeutic target for neuropathic pain conditions

Neurodevelopmental Disorders:

• LRRN4's role in neurite outgrowth suggests involvement in neural circuit formation

• Research approaches:

  • Apply recombinant LRRN4 in neuronal cell cultures to study effects on axon guidance

  • Examine LRRN4 interactions with guidance molecules and synaptic proteins

  • Investigate potential links to neurodevelopmental disorders like autism spectrum disorders

Neurodegenerative Diseases:

• As a synaptic adhesion molecule, LRRN4 may affect synapse stability and maintenance

• Research directions:

  • Study LRRN4 levels in neurodegenerative disease models

  • Investigate whether recombinant LRRN4 can protect against synapse loss

  • Examine interactions with proteins involved in neurodegeneration

Experimental Methodologies:

• Use recombinant LRRN4 immobilized on culture substrates to assess neurite outgrowth inhibition

• Employ tagged recombinant protein in binding assays to identify novel interaction partners

• Develop LRRN4-based probes for identifying specific neuronal populations

The connections between LRRN4, memory formation, and nociceptive pathways suggest it may play broader roles in neurological function and pathology than currently recognized .

How can researchers integrate studies of LRRN4 across different disease models to develop comprehensive therapeutic strategies?

Integrating LRRN4 research across disease models requires a multidisciplinary approach:

Cross-Disease Comparative Analysis:

• Molecular Signature Comparison:

  • Compare LRRN4-associated gene expression profiles across DCM, cancer, and neurological models

  • Identify common and disease-specific pathways affected by LRRN4

  • Use RNA-seq and proteomics to generate comprehensive profiles

• Shared Mechanistic Investigations:

  • Focus on common signaling pathways (Ras/MAPK, PI3K/Akt)

  • Determine tissue-specific binding partners using mass spectrometry

  • Develop unified models of LRRN4 function across tissues

Integrated Research Framework:

Unified Experimental Approaches:

• Generate comprehensive mouse models with tissue-specific LRRN4 modulation

• Develop standardized reagents and assays applicable across disease models

• Establish collaborative research networks spanning cardiology, oncology, and neuroscience

• Use systems biology approaches to model LRRN4's complex roles

Therapeutic Strategy Development:

• Dual-Action Therapeutic Design:

  • Target tissue-specific LRRN4 functions

  • Example: Develop molecules that enhance LRRN4 in cardiac tissue while inhibiting it in cancer contexts

• Precision Medicine Approach:

  • Identify patient populations likely to benefit from LRRN4-targeted therapies

  • Develop biomarkers for LRRN4 pathway activation

• Delivery System Innovation:

  • Design tissue-specific delivery systems for LRRN4 modulators

  • Explore potential for recombinant protein therapy in DCM